Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$8.29 -1.3%	$7.46	$4.02 ▼ $12.73	$447.62M	1.97	1.43 million shs	898,751 shs
GERN Geron	$1.40 -2.1%	$1.35	$1.09 ▼ $4.83	$912.36M	0.73	10.13 million shs	3.41 million shs
LGND Ligand Pharmaceuticals	$161.71 +1.1%	$135.91	$93.58 ▼ $163.34	$3.13B	0.85	310,350 shs	147,031 shs
MNKD MannKind	$4.59 +2.2%	$3.85	$3.38 ▼ $7.63	$1.38B	1.02	3.82 million shs	4.21 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	-2.11%	-9.71%	+29.24%	+32.29%	-5.90%
GERN Geron	+1.42%	0.00%	+25.99%	-7.44%	-68.29%
LGND Ligand Pharmaceuticals	+0.54%	+1.68%	+21.57%	+55.05%	+50.14%
MNKD MannKind	-0.66%	+13.96%	+17.54%	+7.93%	-23.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent Biosolutions	4.628 of 5 stars	3.5	1.0	4.6	3.0	2.5	2.5
GERN Geron	3.0463 of 5 stars	3.3	1.0	1.3	2.3	1.7	0.6
LGND Ligand Pharmaceuticals	4.0302 of 5 stars	1.5	3.0	4.4	4.1	2.5	1.9
MNKD MannKind	3.9094 of 5 stars	3.6	2.0	0.0	3.2	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	3.00	Buy	$14.33	73.00% Upside
GERN Geron	2.56	Moderate Buy	$4.19	199.11% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$165.17	2.14% Upside
MNKD MannKind	3.29	Buy	$9.50	106.97% Upside

Current Analyst Ratings Breakdown

Latest EBS, LGND, GERN, and MNKD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	LGND Ligand Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$157.00 ➝ $206.00
8/26/2025	MNKD MannKind	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $8.00
8/25/2025	MNKD MannKind	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
8/8/2025	LGND Ligand Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$155.00 ➝ $185.00
8/7/2025	MNKD MannKind	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $7.00
7/30/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$145.00 ➝ $162.00
7/23/2025	MNKD MannKind	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $8.00
7/16/2025	MNKD MannKind	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$9.00
7/10/2025	GERN Geron	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$1.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$1.04B	0.42	$1.90 per share	4.37	$10.05 per share	0.82
GERN Geron	$76.99M	11.60	N/A	N/A	$0.41 per share	3.41
LGND Ligand Pharmaceuticals	$167.13M	18.96	$1.62 per share	99.55	$42.28 per share	3.82
MNKD MannKind	$285.50M	4.93	$0.14 per share	32.35	($0.18) per share	-25.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	-$190.60M	$2.45	3.38	4.00	N/A	16.38%	24.63%	8.97%	11/5/2025 (Estimated)
GERN Geron	-$174.57M	-$0.13	N/A	N/A	N/A	-53.52%	-31.37%	-16.01%	11/6/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$4.00	N/A	43.59	N/A	-40.44%	-9.21%	-8.09%	11/6/2025 (Estimated)
MNKD MannKind	$27.59M	$0.11	41.73	19.96	N/A	10.87%	-32.60%	7.81%	11/6/2025 (Estimated)

Latest EBS, LGND, GERN, and MNKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	$1.60	+$0.06	$0.24	$43.87 million	$47.63 million
8/6/2025	Q2 2025	EBS Emergent Biosolutions	-$0.26	$0.16	+$0.42	-$0.22	$148.55 million	$140.90 million
8/6/2025	Q2 2025	GERN Geron	-$0.03	-$0.02	+$0.01	-$0.02	$47.30 million	$49.04 million
8/6/2025	Q2 2025	MNKD MannKind	$0.04	$0.05	+$0.01	N/A	$77.82 million	$76.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.25	5.66	3.00
GERN Geron	0.46	7.87	6.79
LGND Ligand Pharmaceuticals	N/A	5.45	5.21
MNKD MannKind	N/A	2.50	2.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
GERN Geron	73.71%
LGND Ligand Pharmaceuticals	91.28%
MNKD MannKind	49.55%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	1.20%
GERN Geron	7.42%
LGND Ligand Pharmaceuticals	7.00%
MNKD MannKind	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	53.35 million	52.71 million	Optionable
GERN Geron	229	638.02 million	590.68 million	Optionable
LGND Ligand Pharmaceuticals	80	19.60 million	18.23 million	Optionable
MNKD MannKind	400	306.83 million	298.54 million	Optionable

EBS, LGND, GERN, and MNKD Headlines

Recent News About These Companies

MannKind (NASDAQ:MNKD) Stock Price Up 10.4% on Analyst Upgrade

August 29 at 10:45 AM | marketbeat.com

Invesco Ltd. Grows Position in MannKind Corporation $MNKD

August 29 at 3:23 AM | marketbeat.com

MannKind (NASDAQ:MNKD) Shares Up 10.4% Following Analyst Upgrade

August 29 at 2:13 AM | americanbankingnews.com

MannKind to Present at Upcoming Investor Conferences

August 27 at 4:05 PM | globenewswire.com

MannKind (NASDAQ:MNKD) Stock Price Down 5.2% - Here's What Happened

August 27 at 1:38 PM | marketbeat.com

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

August 27 at 8:35 AM | markets.businessinsider.com

MannKind Corporation Collaborates with United Therapeutics to Develop Second Dry Powder Inhalation Therapy

August 27 at 8:31 AM | quiverquant.comQ

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

August 27 at 8:05 AM | globenewswire.com

New Strong Sell Stocks for August 27th

August 27 at 5:51 AM | zacks.com

MannKind (NASDAQ:MNKD) Price Target Raised to $8.00

August 27 at 2:06 AM | americanbankingnews.com

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

August 26 at 5:58 PM | businesswire.com

Vanguard Group Inc. Acquires 1,263,622 Shares of MannKind Corporation $MNKD

August 26 at 3:04 AM | marketbeat.com

MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript

August 25, 2025 | seekingalpha.com

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

August 25, 2025 | benzinga.com

MannKind’s Strategic Acquisition of scPharmaceuticals: A Catalyst for Future Growth and Value Creation

August 25, 2025 | tipranks.com

MannKind (MNKD) to Acquire scPharmaceuticals for $360 Million

August 25, 2025 | gurufocus.com

MannKind’s Strategic Acquisition and Growth Prospects: A Buy Rating by Yun Zhong

August 25, 2025 | tipranks.com

SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders

August 25, 2025 | mms.businesswire.com

MannKind to buy scPharmaceuticals to expand its cardiometabolic business

August 25, 2025 | seekingalpha.com

MannKind to Buy ScPharmaceuticals for Up to $360 Million

August 25, 2025 | marketwatch.com

Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders

August 25, 2025 | mms.businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EBS, LGND, GERN, and MNKD Company Descriptions

Emergent Biosolutions NYSE:EBS

$8.28 -0.11 (-1.25%)

Closing price 03:59 PM Eastern

Extended Trading

$8.33 +0.05 (+0.56%)

As of 08:00 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Geron NASDAQ:GERN

$1.40 -0.03 (-2.10%)

Closing price 04:00 PM Eastern

Extended Trading

$1.42 +0.02 (+1.71%)

As of 06:56 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Ligand Pharmaceuticals NASDAQ:LGND

$161.71 +1.75 (+1.09%)

Closing price 04:00 PM Eastern

Extended Trading

$161.83 +0.12 (+0.07%)

As of 04:39 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

MannKind NASDAQ:MNKD

$4.59 +0.10 (+2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.61 +0.02 (+0.44%)

As of 07:52 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time